Pamela Sung

MD, PhD
Hematologic Oncology

Cancers Treated:

Blood Disorders Leukemia Myelodysplastic Syndrome

Specializing In:

Targeted therapy Molecular Diagnostics Translational Medicine

Research Interests:

FLT3 mutated AML Therapeutic Resistance Epigenetics

About Pamela Sung

Biography:

I joined the faculty at Roswell Park in July 2021 with a dual appointment in the Department of Medicine and Department of Pharmacology & Therapeutics. I am a physician-scientist in the field of leukemia biology. I completed my MD/PhD at New York University and my clinical and post-doctoral training at the Hospital of the University of Pennsylvania. I treat patients with bone marrow cancers (AML, ALL, CML, MDS, and MPNs) and non-malignant blood disorders.  My laboratory focuses on FLT3 mutated AML and improving responses to targeted therapy.

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Department of Medicine - Leukemia
  • Department of Pharmacology & Therapeutics

Background

Education and Training:

  • 2012 - MD - Medicine, New York University School of Medicine, New York, NY
  • 2010 - PhD - Cell and Molecular Biology, New York University, New York, NY
  • 2004 - BA - Biology and Chemistry, Cornell University, Ithaca, NY

Residency:

  • 2012-2014 - Internal Medicine Research Pathway, Hospital of the University of Pennsylvania, Philadelphia, PA

Fellowship:

  • 2014-2018 - Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA

Board Certification:

  • Internal Medicine
  • Medical Oncology
  • Hematology

Professional Memberships:

  • American Society of Hematology
  • American Association for Cancer Research

Professional Experience:

  • 2019-2021 - Instructor of Medicine, University of Pennsylvania, Philadelphia, PA
  • 2018-2019 - Measey Physician Scientist-Fellow, University of Pennsylvania, Philadelphia, PA

Honors & Awards:

  • 2019 - Special Fellow Award, Leukemia and Lymphoma Society
  • 2017 - Research Training Award for Fellows, American Society of Hematology
  • 2017 - Future Leaders Award for Clinical Research in Hematology, Celgene Corporation

Publications

Full Publications list on PubMed

Sung PJ, Selvam M, Riedel SS, Xie HM, Bryant K, Manning B, Wertheim GB, Kulej K, Pham L, Bowman RL, Peresie J, Nemeth MJ, Levine RL, Garcia BA, Meyer SE, Sidoli S, Bernt KM, Carroll M. FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia. Leukemia. 2024 Feb;38(2):291-301. PMID: 38182819

Faisal MS and Sung PJ. Location, location, location: a mini-review of CEBPA variants in patients with acute myeloid leukemia. Leukemia Research Reports. 2023 Aug 27:20:100386. PMID: 37680323.

Martinez-Gutierrez LN, Burgher BC, Glynias MJ, Alvarado D, Griffiths EA, Glenn ST, Sung PJ. Evaluation of hypereosinophilia in a case of FLT3-mutant acute myeloid leukemia treated with gilteritinib. Cold Spring Harb Mol Case Stud. 2023 Jun;9(3). PMID: 37433680.

Sung PJ, Sugita M, Koblish H, Perl AE, Carroll M. Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. Blood Advances. 2019 Apr 9;3(7):1061-1072. PMID: 30944098.

Sung PJ and Luger SM. Minimal residual disease in acute myeloid leukemia. Curr. Treat. Options in Oncol. 2017 Jan;18(1):1-14. PMID: 28110381.